Helen L Ford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4385947/publications.pdf

Version: 2024-02-01

1307366 1125617 16 203 7 13 citations g-index h-index papers 16 16 16 234 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Screening for the risk of job loss in multiple sclerosis (MS): development of an MS-specific Work Instability Scale (MS-WIS). Multiple Sclerosis Journal, 2012, 18, 862-870.	1.4	42
2	A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. Patient, 2018, 11, 391-402.	1.1	32
3	Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. Multiple Sclerosis and Related Disorders, 2019, 27, 370-377.	0.9	22
4	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. Journal of the Neurological Sciences, 2021, 426, 117437.	0.3	19
5	Multiple sclerosis and employment: Associations of psychological factors and work instability. Journal of Rehabilitation Medicine, 2016, 48, 799-805.	0.8	18
6	Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. Multiple Sclerosis and Related Disorders, 2020, 44, 102330.	0.9	13
7	Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Practical Neurology, 2023, 23, 6-14.	0.5	13
8	Psychological determinants of job retention in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 419-426.	1.4	9
9	Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis. Patient Education and Counseling, 2020, 103, 2540-2547.	1.0	8
10	Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102507.	0.9	7
11	The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. Patient, 2020, 13, 583-597.	1.1	5
12	Tortoise or hare? Supporting the chronotope preference of employees with fluctuating chronic illness symptoms. Psychology and Health, 2019, 34, 695-714.	1.2	4
13	Managing the (In)visibility of Chronic Illness at Work: Dialogism, Parody, and Reported Speech. Qualitative Health Research, 2019, 29, 1213-1226.	1.0	3
14	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ Open, 2021, 11, e050176.	0.8	3
15	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. Journal of the Neurological Sciences, 2022, 436, 120188.	0.3	3
16	Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS). Multiple Sclerosis and Related Disorders, 2022, 63, 103894.	0.9	2